<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24885030</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2014</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice.</ArticleTitle><Pagination><StartPage>79</StartPage><MedlinePgn>79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-422X-11-79</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human Enterovirus 71 (EV71) has emerged as the leading cause of viral encephalitis in children, especially in the Asia-Pacific regions. EV71 vaccine development is of high priority at present, and neutralization antibodies have been documented to play critical roles during in vitro and in vivo protection against EV71 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, a novel strategy to produce EV71 vaccine candidate based on recombinant multiple tandem linear neutralizing epitopes (mTLNE) was proposed. The three well identified EV71 linear neutralizing epitopes in capsid proteins, VP1-SP55, VP1-SP70 and VP2-SP28, were sequentially linked by a Gly-Ser linker ((G4S)3), and expressed in E.coli in fusion with the Trx and His tag at either terminal. The recombinant protein mTLNE was soluble and could be purified by standard affinity chromatography. Following three dosage of immunization in adult mice, EV71-specific IgG and neutralization antibodies were readily induced by recombinant mTLNE. IgG subtyping demonstrated that lgG1 antibodies dominated the mTLNE-induced humoral immune response. Especially, cytokine profiling in spleen cells from the mTLNE-immunized mice revealed high production of IL-4 and IL-6. Finally, in vivo challenge experiments showed that passive transfer with anti-mTLNE sera conferred full protection against lethal EV71 challenge in neonatal mice.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results demonstrated that this rational designed recombinant mTLNE might have the potential to be further developed as an EV71 vaccine in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Xiang</ForeName><Initials>YX</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Rui-Yuan</ForeName><Initials>RY</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yong-Qiang</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jian-Feng</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shun-Ya</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Long</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>E-De</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Cheng-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Graduate School, Anhui Medical University, Hefei 230032, Anhui, China. qincf@bmi.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002846" MajorTopicYN="N">Chromatography, Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24885030</ArticleId><ArticleId IdType="pmc">PMC4030048</ArticleId><ArticleId IdType="doi">10.1186/1743-422X-11-79</ArticleId><ArticleId IdType="pii">1743-422X-11-79</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17:371&#x2013;379. doi: 10.1002/rmv.538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.538</ArticleId><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet. 1999;354:987&#x2013;991. doi: 10.1016/S0140-6736(98)11032-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(98)11032-2</ArticleId><ArticleId IdType="pubmed">10501361</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78&#x2013;85. doi: 10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan: Taiwan enterovirus epidemic working group. N Engl J Med. 1999;341:929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao LX, Wu B, Bao WX, Han FA, Xu L, Ge QJ, Yang J, Yuan ZH, Miao CH, Huang XX, Zhang C, Xu H. Epidemiology of hand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. J Clin Virol. 2010;49:100&#x2013;104. doi: 10.1016/j.jcv.2010.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.07.009</ArticleId><ArticleId IdType="pubmed">20719557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VT. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14:e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, Ishiko H, Suzuki H. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J. 2006;25:691&#x2013;694. doi: 10.1097/01.inf.0000227959.89339.c3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000227959.89339.c3</ArticleId><ArticleId IdType="pubmed">16874167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, Sanjoh K, Sakamoto M, Hongo S, Murayama S, Hayasaka K. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol. 2005;43:6171&#x2013;6175. doi: 10.1128/JCM.43.12.6171-6175.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.12.6171-6175.2005</ArticleId><ArticleId IdType="pmc">PMC1317214</ArticleId><ArticleId IdType="pubmed">16333123</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero LJ, Lee CS, Hurrelbrink RJ, Chua BH, Chua KB, McMinn PC. Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997&#x2013;2000. Arch Virol. 2003;148:1369&#x2013;1385. doi: 10.1007/s00705-003-0100-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-003-0100-2</ArticleId><ArticleId IdType="pubmed">12827466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103&#x2013;112. doi: 10.1016/S1875-9572(08)60023-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60023-6</ArticleId><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24:2944&#x2013;2951. doi: 10.1016/j.vaccine.2005.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 2006;8:1671&#x2013;1678. doi: 10.1016/j.micinf.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81:9386&#x2013;9395. doi: 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier vero cell culture. Vaccine. 2007;25:19&#x2013;24. doi: 10.1016/j.vaccine.2006.06.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.06.083</ArticleId><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84:661&#x2013;665. doi: 10.1128/JVI.00999-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, Su IJ, Chong PC, Hsieh SM. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine. 2013;31:2471&#x2013;2476. doi: 10.1016/j.vaccine.2013.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother. 2013;9(8):1701&#x2013;1705. doi: 10.4161/hv.24949.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, AbuBakar S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol. 2010;10:404&#x2013;412. doi: 10.1016/j.meegid.2009.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2009.05.010</ArticleId><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S. EV71: an emerging infectious disease vaccine target in the ear East? Vaccine. 2010;28:3516&#x2013;3521. doi: 10.1016/j.vaccine.2010.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, Shen X, Sun L, Bi S. Generation of neutralizing monoclonal antibodies against enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun. 2009;390:1126&#x2013;1128. doi: 10.1016/j.bbrc.2009.09.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.09.103</ArticleId><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Khong WX, Yan B, Premanand B, Alonso S, Chow VT, Kwang J. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One. 2012;7:e29751. doi: 10.1371/journal.pone.0029751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW. Epitope discovery and their use in peptide based vaccines. Curr Pharm Des. 2010;16:3149&#x2013;3157. doi: 10.2174/138161210793292447.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161210793292447</ArticleId><ArticleId IdType="pubmed">20687873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol. 2003;15:461&#x2013;470. doi: 10.1016/S0952-7915(03)00083-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0952-7915(03)00083-9</ArticleId><ArticleId IdType="pubmed">12900280</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XN, Chen Y, Wu Y, Chen YH. Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker. Vaccine. 2005;23:3630&#x2013;3633. doi: 10.1016/j.vaccine.2005.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.02.008</ArticleId><ArticleId IdType="pubmed">15882522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One. 2011;6:e24626. doi: 10.1371/journal.pone.0024626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024626</ArticleId><ArticleId IdType="pmc">PMC3176274</ArticleId><ArticleId IdType="pubmed">21949735</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, Koestler J, Hanke T, Fagrouch Z, Verschoor EJ, Bontrop RE, Wagner R, Bogers WM, Melief CJ. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS. 2013;27:2842&#x2013;2851.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105029</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6:404&#x2013;414. doi: 10.1038/nrd2224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2224</ArticleId><ArticleId IdType="pubmed">17473845</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Awady MK, El Gendy M, Waked I, Tabll AA, El Abd Y, Bader EI D, EI Shenawy R, Allam A, Abdelhafez TH, Dawood RM. Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy. Vaccine. 2013. http://dx.doi.org/10.1016/j.vaccine.2013.07.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.07.074</ArticleId><ArticleId IdType="pubmed">23962537</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, Xu WB, Qin C, Zhang LF. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Su X, Li X, Li H, Li T, Zhou Z, Zhong T, Zhou R. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One. 2012;7:e41381. doi: 10.1371/journal.pone.0041381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041381</ArticleId><ArticleId IdType="pmc">PMC3407240</ArticleId><ArticleId IdType="pubmed">22848478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Wu CN, Shih SR, Ho MS. Characterization of a vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine. 2002;20:2485&#x2013;2493. doi: 10.1016/S0264-410X(02)00182-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00182-2</ArticleId><ArticleId IdType="pubmed">12057603</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Keogh E, Ishioka G, Sidney J, Tangri S, Livingston B, Mckinney D, Newman M, Chesnut R, Fikes J. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Investig Drugs. 2002;3:132&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, Tangri S, Alexander J, Fikes J, Chesnut R. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens. 2002;59:443&#x2013;451. doi: 10.1034/j.1399-0039.2002.590601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-0039.2002.590601.x</ArticleId><ArticleId IdType="pubmed">12445314</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 2001;19:4652&#x2013;4660. doi: 10.1016/S0264-410X(01)00233-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00233-X</ArticleId><ArticleId IdType="pubmed">11535313</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31:3281&#x2013;3287. doi: 10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, Liu CC. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol. 2010;17:1517&#x2013;1523. doi: 10.1128/CVI.00108-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00108-10</ArticleId><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, Tian X, Jiang T, Qin ED, Qin CF. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J. 2011;8:106. doi: 10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen IC, Wang SM, Yu CK, Liu CC. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol. 2013;202:259&#x2013;265. doi: 10.1007/s00430-013-0289-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-013-0289-y</ArticleId><ArticleId IdType="pubmed">23408291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RY, Dong DY, Liu RJ, Han JF, Wang GC, Zhao H, Li XF, Deng YQ, Zhu SY, Wang XY, Lin F, Zhang FJ, Chen W, Qin ED, Qin CF. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One. 2013;8:e64024. doi: 10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Macary PA, Alonso S, Poh CL. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 2008;21:215&#x2013;224. doi: 10.1089/vim.2007.0089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2007.0089</ArticleId><ArticleId IdType="pubmed">18419256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cello J, Strannegard O, Svennerholm B. A study of the cellular immune response to enteroviruses in humans: identification of cross-reactive T cell epitopes on the structural proteins of enteroviruses. J Gen Virol. 1996;77(Pt 9):2097&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Li HY, Han JF, Deng YQ, Li YX, Zhu SY, He YL, Qin ED, Chen R, Qin CF. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against coxsackievirus A16 in mice. Appl Microbiol Biotechnol. 2013;97:10445&#x2013;10452. doi: 10.1007/s00253-013-5257-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-013-5257-3</ArticleId><ArticleId IdType="pubmed">24085395</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Tian X, Yu M, Qin ED, Qin CF. Producing infectious enterovirus type 71 in a rapid strategy. Virol J. 2010;7:116. doi: 10.1186/1743-422X-7-116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-116</ArticleId><ArticleId IdType="pmc">PMC2892457</ArticleId><ArticleId IdType="pubmed">20525351</ArticleId></ArticleIdList></Reference><Reference><Citation>REED LJ, MUENCH H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 2007;26:361&#x2013;367. doi: 10.1089/dna.2006.0547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2006.0547</ArticleId><ArticleId IdType="pubmed">17570760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RY, Han JF, Jiang T, Tian X, Yu M, Deng YQ, Qin ED, Qin CF. In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors. J Clin Virol. 2011;51:246&#x2013;249. doi: 10.1016/j.jcv.2011.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.05.002</ArticleId><ArticleId IdType="pubmed">21641277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>